Emmanuel Ligner is recorded as Board Member at Avantor, Inc. (AVTR) since January 1, 2025 and CEO at Avantor, Inc. (AVTR). The newest filing on record that lists Emmanuel Ligner as Board Member at Avantor, Inc. (AVTR) is dated March 27, 2026. Avantor, Inc. reported in an 8-K filed August 13, 2025 that Emmanuel Ligner was appointed director, effective August 18, 2025. Avantor, Inc. reported in an 8-K filed July 21, 2025 that Emmanuel Ligner was appointed President and Chief Executive Officer, effective August 18, 2025. The proxy statement of Avantor, Inc. reports total compensation of $5,895,624 for Emmanuel Ligner in fiscal 2025, including a base salary of $379,297. Emmanuel Ligner has spoken on 5 earnings calls across 1 company, most recently for Avantor, Inc. on October 28, 2026. Avantor, Inc. is classified in the Medical Instruments & Supplies industry within the Healthcare sector. Other leadership on record at Avantor, Inc. includes Michael Stubblefield (CEO), Gregory L. Summe (Chairman), R. Brent Jones (CFO) and 7 others.
“On August 7, 2025, the Board of Directors (the "Board") of Avantor, Inc. (the "Company"), upon the recommendation of its Nominating and Governance Committee, elected Emmanuel Ligner as a director with an initial term commencing on August 18, 2025 and expiring on the date of the Company's 2026 Annual Meeting of Stockholders.”
Avantor, Inc. Form 8-K, filed August 13, 2025
· Read the filing
“On July 21, 2025, Avantor, Inc. (the "Company"), announced that it has named Emmanuel Ligner as President and Chief Executive Officer, effective as of August 18, 2025.”
Avantor, Inc. Form 8-K, filed July 21, 2025
· Read the filing
Emmanuel Ligner on recent calls
“A special welcome to Todd on his first earning call with Aventor. Todd will introduce himself shortly, and you will hear much more from him at Investors Day on December 8th.”
“Let me begin with a few financial highlights for the quarter. First quarter results exceeded our expectations due to improved execution in bioscience and medtech product segments, and we have reaffirmed our full year guidance.”
“Before we move to the Q&A session, I want to spend a few moments discussing two important topics our cost-based and our go-to-market strategy i've spent my career in organization famous for their continuous improvement mindset with a particular focus on eliminating wasteful spend and recycling it into gross orientated…”
“As you know, I joined Aventor a little more than two months ago. I came on board because I believe this company has a tremendous potential. I have spent my entire career in pharma and lab science industries, spending meaningful time on three different continents.”
